An Expansion Phase trial of NG11-2 to provide additional insight into the characteristics of HNC patient cohorts and the pharmaceutical effect of NG11-2
Latest Information Update: 19 Nov 2024
Price :
$35 *
At a glance
- Drugs NG11-2 (Primary)
- Indications Mucositis; Radiation-induced abnormalities
- Focus Adverse reactions; Therapeutic Use
- Sponsors VasoDynamics
- 19 Nov 2024 New trial record
- 20 Oct 2024 According to a VasoDynamics media release, following submission of a Clinical Trial Application (CTA) last October, company has completed a positive Ethics Committee meeting and effective communication with the MHRA, with strong support from our Chief Principal Investigator at Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust.
- 20 Oct 2024 According to a VasoDynamics media release, company is looking forward to commencing patient recruitment at 6 NHS oncology centres across the UK over the coming weeks.